JP2008521906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521906A5 JP2008521906A5 JP2007544439A JP2007544439A JP2008521906A5 JP 2008521906 A5 JP2008521906 A5 JP 2008521906A5 JP 2007544439 A JP2007544439 A JP 2007544439A JP 2007544439 A JP2007544439 A JP 2007544439A JP 2008521906 A5 JP2008521906 A5 JP 2008521906A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- transglucosidase
- group
- peptidase
- amylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013142 Amylases Human genes 0.000 claims 13
- 108010065511 Amylases Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001720 carbohydrates Chemical class 0.000 claims 8
- 239000004382 Amylase Substances 0.000 claims 7
- 235000019418 amylase Nutrition 0.000 claims 7
- 102100026189 Beta-galactosidase Human genes 0.000 claims 6
- 108010059881 Lactase Proteins 0.000 claims 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 6
- 102000035195 Peptidases Human genes 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims 6
- 229940111205 diastase Drugs 0.000 claims 6
- 102000038379 digestive enzymes Human genes 0.000 claims 6
- 108091007734 digestive enzymes Proteins 0.000 claims 6
- 235000011073 invertase Nutrition 0.000 claims 6
- 239000001573 invertase Substances 0.000 claims 6
- 229940116108 lactase Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 235000019833 protease Nutrition 0.000 claims 6
- 102000005927 Cysteine Proteases Human genes 0.000 claims 5
- 108010005843 Cysteine Proteases Proteins 0.000 claims 5
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims 5
- 102100022624 Glucoamylase Human genes 0.000 claims 5
- 206010003805 Autism Diseases 0.000 claims 4
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 108010059892 Cellulase Proteins 0.000 claims 4
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims 4
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 4
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 4
- 229940106157 cellulase Drugs 0.000 claims 4
- 108010011619 6-Phytase Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 108090001060 Lipase Proteins 0.000 claims 3
- 102000004882 Lipase Human genes 0.000 claims 3
- 239000004367 Lipase Substances 0.000 claims 3
- 229940088598 enzyme Drugs 0.000 claims 3
- 235000019421 lipase Nutrition 0.000 claims 3
- 229940085127 phytase Drugs 0.000 claims 3
- 241000228245 Aspergillus niger Species 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010004032 Bromelains Proteins 0.000 claims 1
- 101500028128 Homo sapiens Isomaltase Proteins 0.000 claims 1
- 108090000526 Papain Proteins 0.000 claims 1
- 235000019835 bromelain Nutrition 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 229940055729 papain Drugs 0.000 claims 1
- 235000019834 papain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/000,668 US20060115467A1 (en) | 2004-12-01 | 2004-12-01 | Compositions and methods for the treatment of autism |
| PCT/US2005/043175 WO2006060414A2 (en) | 2004-12-01 | 2005-11-30 | Compositions and methods for the treatment of autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521906A JP2008521906A (ja) | 2008-06-26 |
| JP2008521906A5 true JP2008521906A5 (enExample) | 2008-12-18 |
Family
ID=36565652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544439A Pending JP2008521906A (ja) | 2004-12-01 | 2005-11-30 | 自閉症の治療用の組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060115467A1 (enExample) |
| EP (1) | EP1817052A4 (enExample) |
| JP (1) | JP2008521906A (enExample) |
| CN (1) | CN101287829A (enExample) |
| AU (1) | AU2005311975A1 (enExample) |
| CA (1) | CA2590384A1 (enExample) |
| WO (1) | WO2006060414A2 (enExample) |
| ZA (1) | ZA200704677B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| ES2636449T3 (es) * | 2007-06-18 | 2017-10-05 | Et & Ds Company Ltd | Suplemento alimenticio |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| WO2009134964A2 (en) * | 2008-04-30 | 2009-11-05 | Danisco Us Inc. | Enhanced fermentation process using molasses |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| ES2732453T3 (es) * | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| CA3050530A1 (en) | 2009-01-06 | 2010-07-15 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| JP2012514604A (ja) | 2009-01-06 | 2012-06-28 | キュレロン リミテッド ライアビリティ カンパニー | 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法 |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| WO2010147714A1 (en) * | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| WO2011063394A2 (en) * | 2009-11-23 | 2011-05-26 | Olmstead Stephen F | Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| MX362974B (es) | 2011-04-21 | 2019-02-28 | Curemark Llc | Compuestos para el tratamiento de alteraciones neuropsiquiatricas. |
| BR112014016557A8 (pt) * | 2012-01-03 | 2017-07-04 | Curemark Llc | métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US9775887B2 (en) * | 2015-12-14 | 2017-10-03 | Thea Fournier | Enzyme formulation for reducing salicylate intolerance |
| US10195256B2 (en) | 2015-12-14 | 2019-02-05 | Thea Fournier | Enzyme formulation for reducing salicylate and other intolerance |
| CN105652016A (zh) * | 2016-01-28 | 2016-06-08 | 深圳大学 | 一种孤独症检测标志物及其检测方法 |
| GB201614415D0 (en) | 2016-08-24 | 2016-10-05 | Pepsis Ltd | Enzymes for the treatment of human enterometabolic dysfunction |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| TWI658791B (zh) * | 2017-09-25 | 2019-05-11 | 愛之味股份有限公司 | 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法 |
| US12152261B2 (en) * | 2019-02-19 | 2024-11-26 | Dsm Ip Assets B.V. | Method for reducing fructan in a food product with aid of invertase (EC 3.2.1.26) |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| EP4452302A4 (en) * | 2021-12-23 | 2026-04-08 | Access Nutrients Inc | PREVENTION AND TREATMENT OF DISEASES USING A PHYTASE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6042823A (en) * | 1998-07-02 | 2000-03-28 | Amano Pharmaceuticals Co., Ltd. | Enzyme composition and use thereof |
| US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
| US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
-
2004
- 2004-12-01 US US11/000,668 patent/US20060115467A1/en not_active Abandoned
-
2005
- 2005-11-30 WO PCT/US2005/043175 patent/WO2006060414A2/en not_active Ceased
- 2005-11-30 CA CA002590384A patent/CA2590384A1/en not_active Abandoned
- 2005-11-30 EP EP05852432A patent/EP1817052A4/en not_active Withdrawn
- 2005-11-30 CN CNA2005800476252A patent/CN101287829A/zh active Pending
- 2005-11-30 AU AU2005311975A patent/AU2005311975A1/en not_active Abandoned
- 2005-11-30 JP JP2007544439A patent/JP2008521906A/ja active Pending
-
2007
- 2007-06-28 ZA ZA200704677A patent/ZA200704677B/xx unknown
-
2008
- 2008-01-16 US US12/015,444 patent/US20080112944A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080199448A1 (en) | Enzyme composition for improving food digestion | |
| ATE473010T1 (de) | Enzyme für pharmazeutische anwendung | |
| EP2099466B1 (en) | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears | |
| JP2010512795A5 (enExample) | ||
| ATE481883T1 (de) | Milchfreie milchersatzprodukte | |
| RU2007149045A (ru) | Липазы для фармацевтического применения | |
| Kaur et al. | Enzymes as drugs: an overview. | |
| MX2007013725A (es) | Produccion de beta-glucanos y mananos. | |
| RU2008102650A (ru) | Амилазы для фармацевтического применения | |
| WO2008021987A3 (en) | Proteolytic enzyme formulations | |
| DK1162995T3 (da) | Enzymer til behandling af diabetes mellitus type I | |
| RU2011102781A (ru) | ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ | |
| RU2010128654A (ru) | Способ пивоварения | |
| RU2001126526A (ru) | Лекарственное средство, предназначенное для лечения диабета | |
| US20220340842A1 (en) | Glycosyl Hydrolases | |
| NZ623123A (en) | A process for concentration of a polypeptide | |
| WO2003012071A3 (en) | Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use | |
| WO2002074895A3 (en) | Fermentation process including the use of enzymes | |
| WO2002008404A3 (en) | Production of lysosomal enzymes in plants by transient expression | |
| BR0314435A (pt) | Utilização de enzimas da famìlia 8 com atividade xilanolìtica na cozedura | |
| Wang et al. | An acidophilic β-galactosidase from Bispora sp. MEY-1 with high lactose hydrolytic activity under simulated gastric conditions | |
| Kunamneni et al. | Enzymes as therapeutic agents | |
| Kramhøft et al. | Involvement of individual subsites and secondary substrate binding sites in multiple attack on amylose by barley α-amylase | |
| IL155515A0 (en) | Use of enzymes obtained from ciliates as medicaments for promoting digestion | |
| WO2006136160A3 (en) | Proteases for pharmaceutical use |